This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
ICLR Misses on Q3 Earnings, Lowers 2024 Guidance, Stock Falls
by Zacks Equity Research
ICON's third-quarter 2024 earnings lag estimates due to its large customers undergoing significant development model shifts with resulting cost pressures and the biotech market's slower recovery.
EW Q3 Earnings Match Estimates, Revenues Miss, Stock Falls
by Zacks Equity Research
Edwards Lifesciences reports strong contributions from all of the product groups - TAVR, TTMT and surgical structural heart - in the third quarter of 2024.
LH Beats on Q3 Earnings, Raises Revenue Guidance Midpoint, Stock Gains
by Zacks Equity Research
Labcorp beats on earnings and revenues in the third quarter, entering the fourth half of 2024 with robust momentum.
Why Phibro Animal Health (PAHC) is a Top Value Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Is Insulet Stock a Smart Addition to Your Portfolio Right Now?
by Zacks Equity Research
PODD continues to make strides with Omnipod 5 and its market expansion. Robust solvency is a plus.
Finding Great Top-Ranked Momentum Stocks to Buy Now
by Benjamin Rains
The stocks we learn to search for today are top-ranked momentum stocks that might be worth buying to close out October and throughout the last two months of 2024.
PAHC vs. PODD: Which Stock Is the Better Value Option?
by Zacks Equity Research
PAHC vs. PODD: Which Stock Is the Better Value Option?
DGX Stock Rises on Q3 Earnings and Revenue Beat, 2024 Sales View Up
by Zacks Equity Research
Quest Diagnostics' third-quarter 2024 performance reflects impressive DIS business growth and the benefits of new acquisitions.
Brainsway Ltd. Sponsored ADR (BWAY) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Brainsway (BWAY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Is ResMed Stock a Smart Addition to Your Portfolio Right Now?
by Zacks Equity Research
RMD's robust mask business and efforts to boost its SaaS business are encouraging.
Zacks.com featured highlights include Nordstrom, Phibro Animal Health, AllianceBernstein, Carnival and Jackson Financial
by Zacks Equity Research
Nordstrom, Phibro Animal Health, AllianceBernstein, Carnival and Jackson Financial are part of the Zacks Screen of the Week article.
Grab These 5 Relative Price Strength Stocks for Strong Returns
by Nilanjan Choudhury
JWN, PAHC, AB, CCL and JXN are five stocks with explosive relative price strength.
WBA Stock Up on Q4 Earnings & Revenues Beat, Unveils Strategic Action
by Zacks Equity Research
Walgreens reports better-than-expected earnings and revenues in the fourth quarter of fiscal 2024.
Is Phibro Animal Health (PAHC) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Best Momentum Stock to Buy for October 10th
by Zacks Equity Research
TCEHY, EFX and PAHC made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on October 10, 2024.
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
New Strong Buy Stocks for October 10th
by Zacks Equity Research
NEXN, CVNA, PAHC, SOHO and HENKY have been added to the Zacks Rank #1 (Strong Buy) List on October 10, 2024.
Here's Why You Should Retain Penumbra Stock in Your Portfolio Now
by Zacks Equity Research
Investors feel optimistic about PEN's strong growth prospects in the Thrombectomy business. Yet, unfavorable forex impacts are concerning.
Should You Add Quest Diagnostics Stock to Your Portfolio Right Now?
by Zacks Equity Research
DGX's strength in Advanced Diagnostics and robust base business volumes are encouraging.
Reasons to Retain Chemed Stock in Your Portfolio Now
by Zacks Equity Research
Investors feel optimistic about CHE's strong growth prospects in the VITAS business. Yet, unfavorable macroeconomic conditions are concerning.
TMO's New ICP-MS Systems Boost Trace Element Analysis: Stock to Gain?
by Zacks Equity Research
Thermo Fisher introduces the iCAP MX Series ICP-MS to simplify trace elemental analysis.
Reasons to Retain QIAGEN Stock in Your Portfolio for Now
by Zacks Equity Research
Investors feel optimistic about QGEN's strong growth prospects in the NGS platforms. Yet, an unfavorable currency impact on the company's operations is cornering.
New Animal Health Products, Vaccine Sales Support PAHC Stock
by Zacks Equity Research
Phibro Animal Health is focusing on new developments, incremental registrations and volumes of existing vaccine technologies.
Should You Continue to Hold TMO Stock in Your Portfolio?
by Zacks Equity Research
Thermo Fisher advances in its growth strategy, supported by its wave of innovations. However, macroeconomic issues escalate expenses.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.